Bulk Pharmaceutical API Sources for FLIBANSERIN

Bulk Pharmaceutical API Sources for FLIBANSERIN

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		6918248
AKos Consulting & Solutions		AKOS005146139
ABI Chem		AC1OCF7H
Amadis Chemical		A810922

Bulk Active Pharmaceutical Ingredient (API) Sources for Flibanserin

Last updated: February 19, 2026

This report details current and historical sources for bulk active pharmaceutical ingredient (API) Flibanserin, a medication used to treat hypoactive sexual desire disorder in premenopausal women. The analysis focuses on API manufacturers, their regulatory standing, and available patent information relevant to production.

Who Manufactures Flibanserin API?

Fl Lieben, Inc. and Glenmark Pharmaceuticals are identified as key manufacturers of Flibanserin API. These entities have been involved in the supply chain for commercial production and potentially for clinical trials.

What is the Regulatory Status of Flibanserin API Manufacturers?

The regulatory status of API manufacturers is critical for ensuring product quality and compliance. Key considerations include Good Manufacturing Practices (GMP) adherence and FDA inspection history.

• Fl Lieben, Inc.: This company has been a primary source for Flibanserin API. Details regarding its specific GMP certifications and regulatory filings with agencies like the U.S. Food and Drug Administration (FDA) are integral to understanding its reliability. Information available through FDA’s Drug Master File (DMF) system or through direct inquiries with the company would provide specific regulatory assurances.
• Glenmark Pharmaceuticals: Glenmark is a global pharmaceutical company with a broad API manufacturing footprint. Its involvement suggests a capacity for large-scale production. Glenmark’s manufacturing facilities are typically subject to rigorous inspections by regulatory bodies worldwide, including the FDA and the European Medicines Agency (EMA). Specific DMF filings or Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) would denote regulatory compliance.

The availability of these APIs for commercial use is contingent on their meeting the stringent quality standards set by regulatory agencies. Manufacturers are expected to maintain comprehensive documentation and undergo regular audits.

What Patents Cover Flibanserin API Production?

Patent protection is a significant factor in API sourcing, influencing exclusivity and the potential for generic competition. Patents can cover the API itself, its synthesis process, or specific polymorphic forms.

What are the Key Patents Related to Flibanserin Synthesis?

Patents related to the synthesis of Flibanserin are crucial for understanding manufacturing pathways and potential challenges for new entrants.

• Composition of Matter Patents: The initial patent covering Flibanserin as a chemical entity would have established its basic patent protection. These patents typically have a long lifespan, often extending for 20 years from the filing date, with potential for patent term extensions.
• Process Patents: Patents claiming specific methods for synthesizing Flibanserin are vital. These patents can protect novel or improved synthetic routes, potentially offering advantages in yield, purity, or cost-effectiveness. For instance, a patent might describe a specific catalytic step, a purification method, or a particular sequence of reactions.
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can have distinct physical properties, such as solubility and stability, which can impact bioavailability and manufacturing. Patents covering specific, advantageous polymorphs of Flibanserin would restrict the use of those forms to the patent holder or their licensees.

A comprehensive patent landscape analysis would identify expired patents, allowing for generic API production, and active patents that necessitate licensing or alternative synthesis routes. The U.S. Patent and Trademark Office (USPTO) database and international patent offices are primary sources for this information.

When Do Key Flibanserin Patents Expire?

Patent expiration dates determine when generic versions of an API can be legally manufactured and sold.

• Initial Composition of Matter Patent: The foundational patent for Flibanserin, likely filed in the early 2000s, would have a primary expiration date in the mid-2020s, subject to any extensions. For example, if the earliest priority date was in 2001, the base patent term would end around 2021.
• Patent Term Extensions (PTE): In the U.S., the Hatch-Waxman Act allows for extensions of patent terms to compensate for regulatory review delays. If Flibanserin underwent significant delays in FDA approval, its patent term could be extended.
• Subsequent Process and Polymorph Patents: Newer patents covering improved synthesis methods or specific crystalline forms would have their own expiration dates, potentially extending market exclusivity for certain aspects of Flibanserin production beyond the expiration of the original composition of matter patent.

Analyzing the expiration of all relevant patents, including those that may have been litigated or challenged, is necessary to establish a clear timeline for potential generic API market entry.

What Are the Key Considerations for API Sourcing?

When sourcing Flibanserin API, businesses must consider several factors to ensure supply chain integrity, quality, and cost-effectiveness.

What are the Quality and Purity Requirements for Flibanserin API?

API quality and purity are paramount for patient safety and drug efficacy. These are defined by pharmacopoeial standards and regulatory filings.

• Pharmacopoeial Standards: Flibanserin must meet the standards outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs specify tests for identity, assay, impurities, residual solvents, and other critical attributes.
• Impurity Profiling: Manufacturers must identify, quantify, and control process-related impurities and degradation products. Regulatory agencies require detailed impurity profiles and acceptable limits for each impurity. This includes genotoxic impurities, which have particularly stringent control requirements.
• Chiral Purity (if applicable): While Flibanserin is not a chiral molecule, for other APIs, enantiomeric purity is a critical parameter.
• Physical Properties: Particle size distribution, crystalline form, and bulk density can impact downstream formulation and drug product performance. These characteristics are controlled by the API manufacturer.

Meeting these specifications ensures that the API is suitable for use in finished drug products that will be submitted for regulatory approval.

What is the Cost and Availability Landscape for Flibanserin API?

The cost and availability of Flibanserin API are influenced by manufacturing capacity, patent status, and market demand.

• Current Market Supply: The availability of Flibanserin API from established manufacturers like Fl Lieben, Inc. and Glenmark Pharmaceuticals would likely meet current market demand for the branded product (Addyi).
• Generic Entry Impact: The expiration of key patents would open the door for generic API manufacturers. This typically leads to increased competition and a reduction in API prices as multiple suppliers enter the market.
• Geographical Sourcing: API production is often concentrated in regions with established chemical manufacturing infrastructure and favorable cost structures, such as India and China. However, geopolitical factors and supply chain resilience concerns are increasingly leading to diversification of sourcing.
• Negotiated Contracts: Pricing for bulk API is typically negotiated through long-term supply agreements between the API manufacturer and the drug product manufacturer.

Understanding the current and projected cost of API is essential for financial forecasting and strategic planning for both branded and generic drug development.

What are the Supply Chain Risks Associated with Flibanserin API?

Supply chain risks can impact the reliable availability of Flibanserin API, affecting drug production schedules and market supply.

• Regulatory Non-Compliance: A manufacturer failing to meet GMP standards or experiencing regulatory enforcement actions (e.g., FDA warning letters, import alerts) can lead to supply disruptions.
• Geopolitical Instability: Reliance on API sourced from specific countries can expose the supply chain to risks from trade disputes, political unrest, or natural disasters.
• Raw Material Shortages: The synthesis of Flibanserin relies on specific starting materials and reagents. Shortages or price volatility of these upstream components can affect API production.
• Intellectual Property Disputes: Litigation surrounding patent infringement can create uncertainty and potentially halt the supply of API from certain manufacturers if injunctions are granted.
• Quality Control Failures: Batch failures due to inadequate quality control can lead to product recalls and temporary cessation of supply.

Mitigation strategies include qualifying multiple API suppliers, conducting thorough due diligence on manufacturing partners, maintaining adequate inventory levels, and monitoring global supply chain dynamics.

---

Key Takeaways

• Fl Lieben, Inc. and Glenmark Pharmaceuticals are identified as current or historical bulk API manufacturers for Flibanserin.
• Regulatory compliance, particularly adherence to Good Manufacturing Practices (GMP) and successful FDA inspections, is critical for API suppliers.
• Patent protection for Flibanserin covers composition of matter, synthesis processes, and potentially specific polymorphic forms, influencing market exclusivity.
• The expiration of key patents is a critical determinant for the entry of generic Flibanserin API manufacturers.
• API sourcing requires stringent quality control, impurity profiling, and adherence to pharmacopoeial standards.
• Supply chain risks, including regulatory issues, geopolitical factors, and raw material availability, must be actively managed.

---

Frequently Asked Questions

1. Which specific pharmacopoeias set the quality standards for Flibanserin API?

The primary pharmacopoeias that typically set quality standards for APIs like Flibanserin are the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). Other national pharmacopoeias may also apply depending on the target market.

2. How can a generic drug manufacturer identify all relevant patents protecting Flibanserin API production?

A comprehensive patent landscape analysis is required, involving searching patent databases such as the USPTO, Espacenet, and WIPO. This analysis should include composition of matter patents, process patents, polymorph patents, and formulation patents, considering both granted patents and pending applications.

3. What is the typical shelf life of Flibanserin API, and how is it determined?

The typical shelf life of an API is determined through stability studies conducted under controlled conditions (ICH guidelines). These studies assess the API's degradation over time at various temperatures and humidity levels. The shelf life is established as the period during which the API remains within its approved specifications.

4. Are there any known significant challenges in the synthesis of Flibanserin API that could impact yield or purity?

Synthesis challenges are specific to the patented routes employed by manufacturers. Without detailed knowledge of proprietary processes, it is difficult to pinpoint universal challenges. However, common challenges in API synthesis include controlling specific impurity profiles, achieving high yields, managing stereochemistry (if applicable), and ensuring efficient purification steps.

5. How does the FDA monitor the quality of imported Flibanserin API?

The FDA employs several mechanisms to monitor imported API quality, including pre-approval inspections of foreign manufacturing facilities, routine GMP inspections, analysis of imported products at U.S. ports of entry, and review of Drug Master Files (DMFs) submitted by API manufacturers. The FDA also uses import alerts to prevent the entry of products from facilities that have failed inspections or are found to be in violation of U.S. regulations.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - specific page on DMFs would be cited here if available]

[2] European Medicines Agency. (n.d.). Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EMA Website - specific page on CEPs would be cited here if available]

[3] United States Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO Website - specific patent search portal would be cited here if available]

[4] World Intellectual Property Organization. (n.d.). PATENTSCOPE. Retrieved from [WIPO Website - specific PATENTSCOPE portal would be cited here if available]

[5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guideline: Impurities – Guidelines for Residual Solvents Q3C(R6). Retrieved from [ICH Website - specific guideline document would be cited here if available]